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Objective. To assess the efficacy of biologic drugs, beyond tumor necrosis factor- (TNF-) α inhibitors, in the management of
noninfectious refractory scleritis, either idiopathic or associated with systemic immune-mediated disorders. Patients and Methods.
This is a retrospective study assessing the efficacy of several biologic agents (rituximab, anakinra, tocilizumab, and abatacept) and
the small molecule tofacitinib in the treatment of scleritis through assessment of scleral inflammation and relapses, as well as
treatment impact on best-corrected visual acuity (BCVA) and safety profile. Results. Fourteen patients (19 eyes) were enrolled in
the study. Scleritis inflammatory grading significantly improved from baseline to 3 months (p = 0:002) and from baseline to the
last follow-up visit (p = 0:002). Scleritis relapses significantly decreased between the 12 months preceding and following biologic
therapy (p = 0:007). No differences regarding BCVA were observed (p = 0:67). Regarding adverse events, only one patient
developed pneumonia and septic shock under rituximab treatment. Conclusions. Our results, though limited to a low number of
patients, highlight the effectiveness of different biologic therapies in the treatment of noninfectious refractory scleritis, showing to
control scleral inflammation and allowing a significant reduction in the number of relapses.
1. Introduction
Noninfectious scleritis is a severe inflammatory disease of the
white outer coating of the eye frequently associated with
underlying systemic inflammatory diseases, such as rheuma-
toid arthritis, systemic lupus erythematosus, relapsing poly-
chondritis, and systemic vasculitides [1, 2]. The most
aggressive forms of scleritis, such as necrotizing scleritis
and posterior scleritis, represent conditions at high risk of
serious functional and anatomical sequelae. The most
dreaded complication of scleritis is perforation, which can
lead to loss of the eye [1]. Moreover, damage to contiguous
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inflamed ocular structures such as cornea, uvea, and retina
may also occur and leave permanent scarring responsible
for irreversible visual impairment. Early diagnosis in these
cases is paramount, as aggressive treatment with systemic
high-dose glucocorticoids (GCs) in the acute phase and
long-term conventional disease-modifying antirheumatic
drugs (cDMARDs) on the long term is required [1]. In
refractory and most severe cases, several biologics have been
employed to control scleral inflammation. Among biologic
agents, tumor necrosis factor- (TNF-) α inhibitors have
shown to induce a complete and rapid control of scleral
inflammation within a few weeks from the start of treatment
[3, 4]. Beyond TNF-α inhibition, a prospective randomized
double-masked trial by Suhler et al. found that the anti-CD
20 monoclonal antibody rituximab is effective and well toler-
ated during a 24-week follow-up period [5]. However, only
small case series or isolated case reports have been reported
on the use of other different biologics [6–11].
In this regard, we report herein our experience on the
effectiveness of several different biologic agents, with mech-
anism of action different from TNF-α inhibitors, in the
management of noninfectious recalcitrant scleritis.
2. Patients and Methods
2.1. Study Participants and Screening Methodology. We
conducted a retrospective evaluation of patients attending
four tertiary ophthalmologic and rheumatologic clinics for
the management and treatment of inflammatory ocular and
systemic diseases who were affected by noninfectious scleritis
and treated with biologic agents with mechanism of action
different from TNF-α inhibitors. Patients with scleritis effec-
tively treated with systemic TNF-α inhibitors were not
included in this study. Treatment with biologics was estab-
lished for both active noninfectious refractory scleritis and/or
uncontrolled systemic disease associated with scleritis.
The study was approved by the Local Ethic Committee
(Prot. N 14951) and adhered to the tenets of the Declaration
of Helsinki. A written informed consent was obtained by all
study participants or their legal guardians. Patients were
screened for latent or active infections before starting the
biologic agent with exams including chest radiography,
Mantoux or QuantiFERON tests, HBV, HCV, HIV, syphilis,
Borrelia burgdorferi serologies, and urine culture.
The following demographic, clinical, and therapeutic data
were retrospectively collected: age, sex, class I human leuko-
cyte antigen, age at scleritis onset, disease duration, scleritis
relapses, ocular complications, preceding biologic therapy
and cDMARDs, preceding local or systemic GCs, and adverse
events (AEs). Patients were regularly examined every 3
months and in case of necessity (AEs or disease flare) by
either the ophthalmologist or the rheumatologist/internist.
Our study is aimed at evaluating the efficacy of different
biologic agents, beyond TNF-α inhibition, in terms of control
of scleral inflammation, number of ocular relapses, GC-
sparing effect, and visual acuity. Moreover, we recorded the
safety profile of therapies and assessed any ocular complica-
tion occurring during treatment.
2.2. Ophthalmologic and Systemic Work-Up. All study
participants underwent regular complete ophthalmologic
examinations and systemic work-up assessments. Ophthal-
mologic examination included evaluation of best-corrected
visual acuity (BCVA), measurement of intraocular pressure,
complete slit lamp examination, and fundus examination.
Optical coherence tomography was performed to establish
any morphologic macular change at a retinal and choroidal
level. Ocular ultrasonography and/or orbit MR scan were
performed to confirm the diagnosis of posterior scleritis.
Anatomical pattern of scleritis was classified according to
the scheme proposed by Watson and Hayreh [12], whereas
scleral inflammation was evaluated according to the scleritis
grading system proposed by Sen et al. [13], with a score
ranging from 0 to 4+. An extensive multidisciplinary
work-up was also performed to investigate for a potential
underling systemic disease.
2.3. Statistics. Data were analyzed using IBMSPSS Statistics
for Windows, version 24 (IBM Corp., Armonk, NY, United
States). Descriptive statistics was employed to display mean
and standard deviation (SD) or median and interquartile
range (IQR) as appropriate. Normality was assessed by
Shapiro–Wilk test. Repeated ordinal data were computed
with Friedman test followed by post hoc Wilcoxon rank sum
test. Means were compared by unpaired t-test or Mann-
WhitneyU test as needed. The threshold for statistical signif-
icance was set to p < 0:05, and all p values were two sided.
Table 1: Demographic and clinical features of our cohort of 14
patients.
Demographic, laboratory, and clinical data Mean ± SD
Age (years) 47:29 ± 17:73
Age at scleritis onset (years) 42:57 ± 18:54






Eye disease N eyes
Anterior diffuse scleritis 11 (57.89%)
Anterior nodular scleritis 4 (21.05%)
Anterior necrotizing scleritis 1 (5.26%)
Posterior scleritis 3 (15.80%)
Concomitant uveitis 4 (4 AU)
Associated keratitis 3 PUK
Associated systemic disease
Rheumatoid arthritis 7
Granulomatosis with polyangiitis 2
Microscopic polyangiitis 1
Psoriatic arthritis 1
Familial Mediterranean fever 1
AU: anterior uveitis; HLA: human leukocyte antigen; PUK: peripheral
ulcerative keratitis; SD: standard deviation.
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3. Results
Nineteen eyes of 14 patients were included in the study. Most
patients were from Caucasian ancestry (85.7%) except 2 (1
Afro-American and 1 Hispanic). Female patients represented
57% of the study participants. Demographic data, type of eye
involvement, and associated systemic diseases are summa-
rized in Table 1 whereas a detailed description of clinical
characteristics and treatment data of the 14 patients enrolled
is provided in Tables 2 and 3. Biologic therapy was initiated
for active scleritis in 9 out of 14 patients (64.3%) and the
remaining 5 because of the associated systemic disease
(rheumatoid arthritis in 4 patients and granulomatosis with
polyangiitis in one patient). Median ± IQR treatment dura-
tion was 13:5 ± 25:50 months, with a minimum of 1 month,
a maximum of 56 months, and a range of 55 months.
The scleritis grade significantly decreased during the
follow-up period (p < 0:0001). More in detail, a significant
decrease was detected between baseline and 3 months
(median ± IQR 2 ± 4 and 0 ± 1, respectively, p = 0:002) and
between baseline and the last follow-up visit (median ± IQR
2 ± 4 and 0 ± 1, respectively, p = 0:002), while no significant
differences emerged between 3 months and the last follow-
up visit (p = 0:414). Resolution of scleritis was achieved in
10 out of 19 eyes. In the remaining 9 eyes, scleritis improved
in 2 eyes, remained quiescent in 4 eyes, did not improve in 2
eyes, and worsened in 1 eye.
A significant decrease in the number of scleritis relapses
between the 12 months preceding and following biologic
therapy was identified (p = 0:007). A GC-sparing effect was
also observed (mean GCs before treatment was 15:13 ± 9:25
mg/daily of prednisone or equivalent; mean GCs at last
follow-up was 5:14 ± 4:63mg/daily of prednisone or equiva-
lent; p = 0:016).
With regard to AEs, only one patient developed a
serious adverse event (pneumonia and septic shock) 1
month after the introduction of rituximab. The following
ocular complications developed in 6 eyes: cataract (n = 3),
scleral thinning (n = 3), infectious keratitis that required
tectonic patch because of impending perforation (n = 1),
and macular subatrophy (n = 1). No significant differences
regarding BCVA values were observed between baseline and
the last follow-up visit (median ± IQR 10 ± 3 and 10 ± 1,
respectively) (p = 0:67).
4. Discussion
The advent of biologic therapy has revolutionized the
management of noninfectious intraocular inflammation.
However, most of the reported literature is primarily focused
in the treatment of uveitis [14], whereas the efficacy and
safety of biologics in scleritis have mainly been addressed
by single case reports and small case series [6–11, 15].
Based on our findings, therapy with different biologic
agents has resulted in a rapid control of scleral inflammation
within 3 months from the start of treatment. Similar results
were reported in other studies as well. Treatment with the
interleukin- (IL-) 1 receptor antagonist anakinra resulted in
a rapid improvement within 1 month in a case series of 10
consecutive patients affected by severe and refractory nonne-
crotizing scleritis [7]. Silpa-Archa et al. reported the achieve-
ment of inflammation control with steroid-sparing effect in
50% of their scleritis patients under the IL-6 inhibitor
tocilizumab. They also observed a faster response to toci-
lizumab in scleritis compared to patients with uveitis [10].
In our cohort, alongside the rapid efficacy in controlling
scleral inflammation, scleritis grade decreased significantly
also from baseline to the last follow-up visit, which advo-
cates for a prolonged effectiveness over time. Additionally,
we also observed a significant decrease in the number of
scleritis relapses.
Table 2: Clinical characteristics and past treatments of 14 patients enrolled.
Patient Age/sex Anatomical pattern Laterality Systemic disease Preceding biologics and their dose
1 42/M Nodular AS Bilateral GPA —
2 76/M Necrotizing AS Unilateral MPA —
3 66/M Diffuse AS Unilateral RA —
4 16/F Posterior scleritis Unilateral Idiopathic —
5 32/F Diffuse AS Unilateral GPA —
6 56/F Diffuse AS Bilateral RA ADA (40mg/2 weeks), ABA (125mg/week), IFX (5mg/kg/4 weeks)
7 46/M Diffuse AS Unilateral PsA ADA 40mg/2 weeks, IFX (5mg/kg/4 weeks)
8 18/F Posterior scleritis Unilateral Idiopathic RTX (2 gr/6 months)
9 59/M Nodular AS Bilateral RA —
10 66/M Posterior scleritis Unilateral FMF —
11 54/F Diffuse AS Bilateral RA ADA (40mg/2 weeks)
12 52/F Diffuse AS Unilateral RA —
13 34/F Diffuse AS Unilateral RA —
14 45/F Diffuse AS Bilateral RA
ETN (50mg/week), ADA (40mg/2 weeks), TCZ (162mg/week),
RTX (2 gr/6 months)
ABA: abatacept; ADA: adalimumab; AS: anterior scleritis; F: female; GPA: granulomatosis with polyangiitis; IFX: infliximab; M: male; MPA: microscopic





























































































































































































































































































































































































































































































































































































































































































































































































































































































4 Mediators of Inflammation
Among biologic treatment, B cell-depletion therapy
seemed to be another feasible option in achieving a
longstanding scleritis remission [5, 11]. Indeed, Suhler et al.
found the anti-CD 20 monoclonal antibody rituximab to be
effective and well tolerated on a 24-week period in patients
affected by refractory scleritis. Interestingly, no notable
differences in terms of efficacy and toxicity were found
between patients receiving 500mg and those receiving
1000mg of rituximab [5]. In a retrospective case series of 15
patients with a mean follow-up of 34 months, rituximab was
shown to be effective for recalcitrant noninfectious scleritis
and in some cases resulted in a long-term durable drug-free
remission. However, the authors stated that aggressive rituxi-
mab regimens with higher dosages were required to maintain
steroid-free remission [11]. One of our patients (patient 4)
treated with rituximab did not show any improvement of
scleral inflammation. She was initially diagnosed with an
orbital inflammatory disease and was therefore prescribed
rituximab based on recent reports of its efficacy in this condi-
tion [16, 17]. She is now under investigation to start an anti-
TNF-αmonoclonal antibody.
In this regard, we could not evaluate any potential statis-
tical difference between various treatment regimens, due to
the low number of patients treated with rituximab included
in our study.
Concerning to visual function, 14 out of 19 eyes (73.68%)
presented with a BCVA ≥ 9 at baseline. Therefore, the lack of
significant differences between baseline and the last follow-
up visit suggests an ability of biologic therapy to preserve
visual acuity over time in scleritis patients.
To the best of our knowledge, we report the first cases of
refractory scleritis treated with the recombinant fusion
protein abatacept and the Janus kinase inhibitor tofacitinib.
More in detail, among the 4 patients (6 eyes) treated with
either abatacept or the small molecule tofacitinib, all had an
active anterior diffuse scleritis at baseline and all but one
achieved resolution of ocular inflammation at the last
follow-up visit.
Several biologic agents with a different mechanism of
action from anti-TNF-α inhibitors were found to be effective
in most of our patients. However, in some cases, the above-
mentioned drugs did not show the same efficacy. This is
likely to be explained by the heterogeneity of our sample
determining distinct pathogenetic backgrounds in accor-
dance to different systemic diseases encountered in our
cohort. Therefore, in addition to its anatomical pattern,
scleritis treatment should be ideally tailored also by taking
into account the associated systemic disorder. In case of
idiopathic scleritis, the response to treatment may vary due
to the possible activation of different unknown underlying
pathogenetic pathways.
However, with the expanding number of biologics avail-
able, the prognosis of scleritis, either idiopathic or associated
with systemic immune-mediated disorders, may experience a
radical change.
To date, we are far from drawing firm conclusions, and
our current limited knowledge warrants further studies pro-
spectively designed with larger samples of patients to shed
light on this topic. Indeed, our present study comprises
several limitations, including its retrospective design, the
small sample size, and therapeutic heterogeneity with
different biologic agents employed before study entry and
within study period.
In conclusion, our results highlight the effectiveness of
several biologic agents in the treatment of noninfectious
refractory scleritis, showing their potential ability in
controlling scleral inflammation and determining a signifi-
cant reduction in the number of relapses, while preserving
visual acuity and displaying an excellent safety profile.
Data Availability
The data used to support the findings of this study are
available from the corresponding authors upon request.
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